Pharmaceutical Pricing April 2026 Weighted Average Determination

AU Federal Legislative Instruments (7-day)

Published March 5th, 2026

Detected April 1st, 2026

Summary

The Australian Department of Health and Aged Care issued a legislative instrument establishing weighted average disclosed prices for specific pharmaceutical brands and setting the April 2026 reduction day under the National Health Act 1953. This determination affects approved ex-manufacturer prices for PBS-listed medicines. The instrument is filed as F2026C00279.

View original document View source feed page

What changed

The National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025 establishes weighted average disclosed prices for pharmaceutical brands listed in Schedules 1 and 2, and sets the reduction day for April 2026. The instrument defines adjusted approved ex-manufacturer prices and specifies when price reductions take effect. F2026C00279 was registered on 5 March 2026.

Pharmaceutical companies and healthcare providers supplying PBS-listed medicines should review the schedules to identify affected brands and ensure systems are updated for the April 2026 reduction day. Suppliers should verify pricing calculations align with the weighted average methodology specified in this determination.

What to do next

Review Schedule 1 and Schedule 2 brand listings to identify affected pharmaceutical products
Update pricing systems with new weighted average disclosed prices before April 2026 reduction day
Verify adjusted approved ex-manufacturer prices comply with determination requirements

Source document (simplified)

- Interactions

National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025

In force Administered by
- Department of Health, Disability and Ageing
This item is authorised by the following title:

National Health Act 1953 Latest version View as made version F2026C00279 C01 05 March 2026

View document Legislative instrument Filter active Table of contents
- Volume 1
- 1 Name
- 2 Commencement
- 3 Repeal
- 4 Authority
- 5 Definitions
- Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day
- 6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1
- 7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items
- 8 Reduction Day
- Part 2 – Brands of pharmaceutical items with a weighted average disclosed price
- 9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2
- Volume 2
- Volume 3

Named provisions

Part 1 – Brands of pharmaceutical items with a weighted average disclosed price Section 6 - Weighted average disclosed price for brands of pharmaceutical items in Schedule 1 Section 7 - Adjusted approved ex-manufacturer price for brands of pharmaceutical items Section 8 - Reduction Day Part 2 – Brands of pharmaceutical items with a weighted average disclosed price Section 9 - Weighted average disclosed price for brands of pharmaceutical items in Schedule 2